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Abstract
Background and Purpose: Molecular profiling should be performed on all advanced non-small cell lung cancer with non-
squamous histology to allow treatment selection. Currently, this should include EGFR mutation testing and testing for ALK
rearrangements. ROS1 is another emerging target. ALK rearrangement status is a critical biomarker to predict response to
tyrosine kinase inhibitors such as crizotinib. To promote high quality testing in non-small cell lung cancer, the European
Society of Pathology has introduced an external quality assessment scheme. This article summarizes the results of the first
two pilot rounds organized in 2012–2013.
Materials and Methods: Tissue microarray slides consisting of cell-lines and resection specimens were distributed with the
request for routine ALK testing using IHC or FISH. Participation in ALK FISH testing included the interpretation of four digital
FISH images.
Results: Data from 173 different laboratories was obtained. Results demonstrate decreased error rates in the second round
for both ALK FISH and ALK IHC, although the error rates were still high and the need for external quality assessment in
laboratories performing ALK testing is evident. Error rates obtained by FISH were lower than by IHC. The lowest error rates
were observed for the interpretation of digital FISH images.
Conclusion: There was a large variety in FISH enumeration practices. Based on the results from this study, recommendations
for the methodology, analysis, interpretation and result reporting were issued. External quality assessment is a crucial
element to improve the quality of molecular testing.
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Introduction
Lung cancer is amongst the leading causes of cancer related
mortality worldwide [1]. Approximately 85% of lung cancers are
non-small cell lung cancers (NSCLC), traditionally divided into
three major cell types: adenocarcinoma, squamous cell carcinoma
and large cell carcinoma [2]. Over the past decade, the availability
of molecular targeted therapies has increased the progression-free
survival for patients with NSCLC, adenocarcinoma in particular
[3–6].
The approach of using biomarkers to select treatments that are
tailored to individual patient profiles is referred to as precision
medicine. In advanced NSCLC, EGFR gene mutations and ALK
rearrangements are currently critical biomarkers to predict
treatment response. The fusion protein from ROS1 rearrangement
is an emerging target.
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In 2007, it was first reported that an inversion on chromosome
2p resulted in the creation of an EML4-ALK fusion gene in lung
cancer [7]. Multiple EML4-ALK variants, represented by different
EML4 breakpoints, have been identified, as well as other fusion
partners for ALK, such as KIF5B and TFG [8–10]. ALK
rearrangements result in oncogenic fusions which lead to
constitutive activity of the ALK tyrosine kinase with subsequent
effects on proliferation, migration and survival [11]. Lung cancers
harboring ALK rearrangements represent a unique subpopulation
of lung cancer patients. The frequency of the EML4-ALK
rearrangement ranges from 2% to 7% in unselected NSCLC
patients [3,12]. The frequency is higher in NSCLC patients with
adenocarcinoma histology, non or light cigarette smoking history,
and younger age, regardless of ethnicity [3,12,13]. However, these
clinical characteristics are not shared by all carriers and molecular
characterization is necessary to determine treatment eligibility
[3,14,15].
ALK rearrangements are pharmacologically targetable with the
small molecule tyrosine kinase inhibitor (TKI) crizotinib. In 2011,
the FDA granted accelerated approval of crizotinib in response to
the manifested clinical benefit.
Routine molecular diagnostics need to include evaluations for
both EGFR mutations and ALK rearrangements [13,15,16]. It is
expected that testing for ROS1 rearrangements will be included
soon. ROS1 is another receptor tyrosine kinase that forms fusions
in NSCLC and has shown responsiveness to crizotinib [17].
Diagnostic testing laboratories have been expected to rapidly
introduce and perform molecular testing for NSCLC. For
successful patient treatment, it is of great importance that
molecular test results are accurate, highly reliable, and presented
in a timely fashion. In 2012, the European Society of Pathology
(ESP) proposed an external quality assessment (EQA) scheme to
promote high quality biomarker testing in NSCLC for EGFR
mutation analysis and ALK rearrangement detection. From 2014
on, ROS1 testing is also included. The scheme aims to assess and
improve the current status of molecular testing in NSCLC, to
provide education and remedial measures, to permit inter-
laboratory comparison and to allow validation of test methods
by distributing validated material harboring well-defined aberra-
tions. For EGFR, EQA results have been reported [18]. This
article summarizes the results of the two ALK testing pilot rounds
of the ESP Lung EQA scheme, organized in 2012–2013 with the
purpose to reflect the current status of ALK rearrangement testing
practices and to issue recommendations for the improvement of
testing quality.
Materials and Methods
A pilot EQA scheme consisting of two rounds was set up. Tissue
microarray (TMA) slides that consisted of NSCLC cell-lines and
resection specimens were distributed. Three expert laboratories
(University of Groningen, the Netherlands, UK NEQAS ICC &
ISH, United Kingdom and VU University Medical Center,
Amsterdam) provided material for this EQA program. All patient
samples were leftover tissues that were obtained as part of routine
care and testing from the three laboratories mentioned above and
then handed over to the researchers anonymously. These
laboratories signed a statement that the patient material was
obtained according to the national legal requirements for the use
of patient samples. Informed consent is not a mandatory
prerequisite for the use of patient derived material, since samples
for test validation are exempt from research regulations requiring
informed consent. The treating physician was responsible to
obtain informed consent from the patients to use their tissues and
data for research purposes and this consent is kept in the patient’s
medical file. The authors had no contact with the patients or
received any patient identifying information. The samples were to
be analyzed for the presence of ALK rearrangements using IHC or
FISH. In addition to the TMA slides, participation in ALK FISH
included the interpretation of four digital FISH images which were
accessible online. The ALK FISH digital cases were provided in
close collaboration with UK NEQAS ICC & ISH.
In both rounds, mock clinical information was provided for
several cases, for which the delivery of a full written report was
requested. Report content was assessed in agreement with
established standards/guidelines on reporting [19–21].
A central database was used for the submission of the results,
accessible through the ESP Lung EQA Scheme website. Through
their personal account, participants could access their results,
scheme documentation and assessor feedback. Upon registration,
each laboratory was assigned a unique EQA identity number to
guarantee anonymity. A team of medical and technical experts
supported the validation of the samples and the evaluation of the
scheme results. Results were discussed during an assessment
meeting to obtain final consensus scores. Participants received
individual feedback and a general report with aggregated scheme
results.
The set-up of both rounds slightly differed and the scheme was a
pilot for the development and standardization of homogeneous
testing material. Eight samples (four resection specimens and four
cell lines) and twelve samples (six resection specimens and six cell
lines) were prepared and send to the participants for respectively
the first and second round. Different cell lines either with or
without ALK break were routinely fixed with neutral-buffered
formalin, mixed with agar and embedded in paraffin (reflecting
routine pathology tissue block) were included. Results from
samples for which less than 75% of the participants were able to
obtain a result were not taken into account to assess performance
[22]. Consequently, for ALK FISH, 3/8 and 7/12 samples were
regarded as educational samples for respectively the first and
second round. For the assessment, the accepted cases were two
resection specimens and three cell lines for the first round of ALK
FISH, and for the second round, five resection specimens were
included. For ALK IHC, all samples were approved in both
rounds.
For ALK FISH, it was requested for each case to report the
number of neoplastic cell nuclei without hybridization signals, the
number of neoplastic nuclei with fused signal, with split signal and
with a single red signal. An algorithm automatically generated the
number of neoplastic nuclei with FISH signal, the number of
neoplastic nuclei with split or single red, and the fraction of FISH
positive and negative nuclei. Participants were asked to then
determine the outcome of the ALK FISH test (positive/negative).
Samples for which a laboratory did not obtain results due to
sample quality or technical failures were not assessed. For ALK
FISH TMA and ALK FISH Digital, error rates were calculated
based on the samples for which a minimum of 50 nuclei were
enumerated, in order to exclude uninformative cases. This paper
does not emphasize the marking criteria and assigned scores, as
the scoring criteria slightly differed for the pilot rounds, but the
study aims to reflect the current status of ALK rearrangement
testing practices in molecular pathology laboratories.
For ALK IHC, it was requested to use the H-score procedure as
described by Ruschoff et al. [23]. This modified H-score
procedure is educational as it gives a better understanding of the
ALK IHC sensitivity and reliability [14]. In the first round, a cut-
off IHC score of 32 was determined by the mean score plus
standard deviation from the laboratories on the IHC negative
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specimens (except outliers with H-score .100). The same
threshold for positivity/negativity was applied in the second
round.
For the statistical analysis, scheme error rates from both rounds
for FISH digital and FISH TMA were compared using the Mann-
Whitney U test. Scheme error rates for IHC were compared using
an unpaired t-test. The level of significance was set at a=0,05.
Results
In total, 173 different laboratories (primarily from European
Union countries) participated in the pilot rounds. In the first
round, 29 laboratories submitted results for ALK IHC, 55 for ALK
FISH TMA, and 67 laboratories performed the interpretation of
the digital ALK FISH images. In the second round, 58 laboratories
submitted results for ALK IHC, 104 for ALK FISH TMA, and
106 for the ALK FISH digital cases. For the data-analysis, missing
values were ignored and only valid answers to questions were
included, which explains why sample sizes slightly differ.
Laboratory characteristics are listed in Table 1. The total number
of laboratories that provided information was used as the
denominator to calculate percentages. Because it was sometimes
possible to indicate more than one answer, percentages may not
add up to 100%.
The majority of the participants were set in a community
hospital or university hospital environment. The analysis was
mostly performed under the authority of the department of
pathology. Regarding the interpretation of ALK FISH, a
pathologist was most frequently involved (23% and 27% of
laboratories in the first and second round, respectively), in some
cases assisted by a scientist (18% and 27%) or a technician (20%
and 13%). A scientist alone performed the FISH reading in 15% of
the laboratories in both the first and second round. The final
reading conclusion was the responsibility of a pathologist alone in
more than half of the laboratories (52% and 59% in the first and
second round). A pathologist in cooperation with a scientist was
responsible in 13% and 14% of the laboratories. A scientist alone
was responsible for the final reading conclusion in 16% and 12%
of the laboratories in the first and second round.
ALK FISH digital results
Results for both rounds of the ALK FISH digital subscheme are
summarized in Table 2. There were no clear differences in the
error rates depending on the number of nuclei enumerated.
Enumeration practices were evaluated on sample level and on
laboratory level. In both rounds, the bulk of the participants
enumerated 50–100 nuclei for each case. At laboratory level, in
the first round, 34/67 laboratories (51%) counted $50 cells for
each sample. In the second round, an increase was observed to
77/106 (73%). Table 3 illustrates the performance of the labs that
participated in both rounds for each subscheme. Improvement in
enumeration practices was defined as enumeration of $50 cells in
a larger number of samples in the second round compared to the
first round.
A decrease was observed in the error rates between both rounds
(error rates were calculated taking only the samples for which $50
nuclei were enumerated into account). In the first round, 7 out of
195 scored samples were incorrectly assigned (3,6%), while in the
second round, 4 errors out of 366 scored samples (1,1%) occurred.
The comparison of the number of errors made for laboratories
Table 1. Laboratory characteristics.
Laboratory characteristics Round 1 Round 2
N % (n=67) N % (n=149)
Laboratory settings Community Hospital 30 48% 80 54%
University Hospital 24 36% 30 20%
University 6 9% 17 11%
Private 3 4% 16 11%
Industry 2 3% 3 2%
Private Hospital 0 0% 2 1%
Other 2 3% 1 1%
Clinical tests offered
on lung biopsy samples
in routine diagnostics
ALK rearrangement
detection
56 84% 110 74%
EGFR mutation
detection
/ / 128 86%
KRAS mutation
detection
/ / 112 75%
Analysis performed under
the authority of the
department of pathology
Yes 61 91% 116 78%
No 6 9% 33 22%
Tests most frequently
ordered on lung biopsies
EGFR / / 132 89%
ALK / / 49 33%
KRAS / / 44 30%
None of the above / / 7 5%
doi:10.1371/journal.pone.0112159.t001
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that participated in both rounds and that counted $50 nuclei for
each case can be found in Table 3.
ALK FISH TMA results
Table 4 summarizes the ALK FISH TMA results for both
rounds. In both rounds, the majority of the participants
enumerated 50–100 nuclei for each case. Again, there were only
small differences in the error rates depending on the number of
nuclei enumerated. In the first round, 30/55 laboratories (55%)
counted $50 cells for each sample; in the second round there was
an increase to 81/104 (78%).
For the TMA cases there was also a decrease in the error rates
between the two rounds. In the first round, 14 out of 193 scored
samples were incorrectly assigned (7,3%), while in the second
round, 22 errors out of 423 scored samples (5,2%) occurred.
Comparison of the enumeration performance and number of
errors made for laboratories participating in both rounds can be
found in Table 3.
ALK IHC results
Results for both ALK IHC rounds are provided in Table 5. In
the first round, 30/230 scored cases (13,0%) were incorrectly
called (false positive or false negative). In the second round, a
decrease to 44/540 (8,2%) was observed. Table 3 illustrates the
performance for the labs that participated in both IHC rounds.
Summary scheme error rates
The Mann-Whitney U test revealed no significant differences
between both rounds for Digital FISH (U=7, z= –0.308,
p = 0.758) or FISH TMA (U=9, z = –0.731, p = 0.465). For
IHC, an unpaired t-test showed no significant difference between
the first (M=0.13, SD=0.06) and second round (M=0.08,
SD=0.05); t(18) = 1.845, p= 0.082. Although not statistically
significant, comparing the error rates in both rounds suggests a
learning effect (Table 6). The smallest error rates were observed
for the digital cases, assessing only the post-analytical interpreta-
tion phase. In both rounds, the error rate for ALK FISH TMA was
lower than the error rate for ALK IHC TMA.
Methods used
The most frequently used method for FISH analysis was the
Vysis ALK break apart FISH probe kit (Abbott Molecular, Illinois,
USA), used by over 70% of the participants. For IHC, the most
frequently used antibodies were clone 5A4 and clone D5F3 for the
first and second round, respectively. An overview of the used
methods and the error rate per method is provided in Tables 7
and 8. For the percentage of laboratories that used a certain
method, the total number of laboratories that provided informa-
tion was used as the denominator. Because it was possible to
indicate more than one used method, percentages may not add up
to 100%.
For ALK FISH, the Repeat-Free Poseidon ALK/EML4 t(2;2)
inv(2) Fusion Probe (Kreatech Diagnostics, Amsterdam, the
Netherlands) revealed a high error rate of 50% in the second
round (Table 7). For IHC, the smallest error rates were observed
for clones 5A4 and D5F3 (Table 8).
Clinical result reporting
Evaluation of the written reports for the second round (n= 102)
showed that a case-specific clinical interpretation was missing in
74% and 79% of the reports for an ALK positive and ALK
negative case, respectively. Patient name and date of birth were
correctly present in the majority of the reports, as well as a
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specification of the methods used (FISH kit information or IHC
antibody). However, a specification of the aberrations tested and
the threshold of the method were not mentioned in 46% and 47%
of the FISH reports. The total number of neoplastic cells analyzed
and the number of cells with split and/or single signal were
missing in 23% of the FISH reports. For IHC, the threshold for
positivity/negativity was not defined in 81% of the reports, and the
staining intensity was missing in 39% of the reports.
Discussion
Major advances have been made in the management of patients
with NSCLC, with improved treatment response and survival
following the introduction of molecular targeted TKI therapies
focusing on EGFR mutations and ALK rearrangements. The
increasing importance of morphology-based studies such as IHC
or FISH has made the pathologist’s involvement a key element in
precision medicine for NSCLC [2,24].
In reply to the growing demands, laboratories have introduced
molecular testing for NSCLC in routine diagnostics. Regular
participation in quality assurance programs is crucial to ensure a
high quality of testing service and to warrant patient safety
[15,18,19].
Our results show that in the majority of the participating
laboratories, ALK testing is performed under the authority of the
pathology department. This is a necessity as FISH and IHC are
both histological tests. Pathology review and assessment of section
quality is essential considering the diversity and heterogeneity of
tumor tissue [19], as false negatives may be due to poor fixation or
insufficient neoplastic cell content [14,18].
Three methods are generally used in routine diagnostics for
ALK rearrangement detection: FISH, RT-PCR, and immunohis-
tochemistry for aberrant expression of ALK protein [12,14,25].
Importantly, every assay should undergo validation in the
laboratory before clinical interpretation and should be subject to
regular internal and external quality controls [14,19,24]. The FDA
approved test to determine ALK status is the Vysis LSI ALK dual
color, break apart rearrangement probe (Abbott Molecular,
Illinois, USA) [12,14]. Although other IVD-CE labeled kits are
available in Europe, this kit was by far the most frequently used
method in both pilot rounds. ALK break apart (or split-signal)
probes detect disruption of the ALK 2p23 locus but do not identify
the partner fusion gene [3,25]. Surprisingly, the ALK/EML4
fusion probe is still occasionally used, although these probes miss
the translocation of ALK with partners other than EML4. In the
second round, the fusion probe revealed a high error rate of 50%.
The cut-off values used during the clinical trials to prove the
efficacy of crizotinib can be transferred from the Vysis probe to
other break apart probes since the design (size + location) is highly
similar [26]. The ZytoLight TriCheck (ZytoVision, Bremerhaven,
Germany), used by approximately 7% of the participants in both
rounds, can identify the presence of an ALK rearrangement and if
the rearrangement partner is EML4. Today it is still under
discussion whether it is important to know the fusion partner of
ALK in relation to expected response to ALK TKIs [27,28].
According to Abbott Molecular scoring criteria, a nucleus is
considered positive if it contains at least one split signal or one
isolated red signal. A first enumerator should count 50 nuclei.
Cases with .50% and ,10% positive nuclei are considered
positive and negative respectively. If a sample shows between 10–
50% positive nuclei, a second enumerator should also count 50
nuclei. If the average of the two readings contains at least 15%
positive cells, the sample is considered positive. The kit specifies
uninformative specimens as those in which fewer than 50 nuclei
within the scribed area can be enumerated. In our evaluation these
cases were therefore not included to calculate and compare the
scheme error rates. It has been shown that the sensitivity and
specificity of the kit increase as the number of tumor areas and
number of nuclei scored increase [29,30]. Our results showed that
ALK rearrangement status was often determined on the evaluation
of less than 50 nuclei by many participants. The percentage of
false positive and false negative results upon enumeration of ,50
nuclei did not reveal a clear difference compared to the percentage
upon enumeration of $50 tumor nuclei. These findings correlate
with the fact that the ALK rearrangement appears to be a
homogenous event in the tumor population [26,29], Enumeration
of ,50 nuclei is not advisable because this number is based on the
minimal number that is statistically needed to be able to reliably
define a sample without FISH break signals (,15% of nuclei) as a
case without ALK rearrangement. In addition, the predictive value
of phase III trial is based on this. Remarkably, some participants
enumerated a large number of nuclei (e.g. .600 evaluated nuclei
for case 12.215), which is not a requirement for daily practice.
FISH interpretation should be performed in areas of the slide with
clear signals, which are clearly distinct from the nuclear
fluorescent ‘noise’ as well as from the background [15].
Importantly, selection of neoplastic nuclei is essential, and to this
end sufficient morphological knowledge in FISH stained slides is
obligatory, which stresses involvement of a pathologist.
It is not a surprise that the TMA FISH error rates were
substantially higher than those of the digital FISH images. The
FISH digital subscheme specifically assesses the interpretation of
identical digital images whereas the TMA FISH error rate also
incorporates variation in serial TMA sections, technical execution,
and reading. Suboptimal ALK FISH procedure may lead to a low
signal versus background ratio, increasing the chance for
interpretation errors.
Although FISH is used as a standard test, it demonstrates
considerable inter-observer variability. Therefore, experienced (.
100 cases/year) and well-trained FISH reviewers/enumerators are
necessary. If the clinical scientist is well trained and experienced in
histo- and cytomorphology with specialized training in solid tumor
Table 3. Performance of laboratories that participated in both rounds.
Subscheme
Nr of labs with
improved
enumeration
performance
Nr of labs
with equal
enumeration
performance
Nr of labs
with worse
enumeration
performance
Nr of labs
with a
decrease in
nr of errors
Nr of labs
with equal
nr of errors
Nr of labs
with higher
nr of errors
ALK FISH Digital 14/39 (36%) 22/39 (56%) 3/39 (8%) 1/37 (3%) 36/37 (97%) 0/37 (0%)
ALK FISH TMA 13/35 (37%) 17/35 (49%) 5/35 (14%) 7/29 (24%) 20/29 (69%) 2/29 (7%)
ALK IHC / / / 3/14 (21%) 9/14 (64%) 2/14 (14%)
doi:10.1371/journal.pone.0112159.t003
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FISH analysis, he/she can be responsible for the technical
performance and molecular interpretation. A pathologist should
at least be responsible for the selection of the right cells, the review
of the interpretation and the authorization of the pathology report
[14,15]. Our data demonstrate that a pathologist was responsible
for the final conclusion in the majority of the laboratories.
Participating laboratories indicated that scientists and technicians
were often involved in FISH enumeration. In this set-up it is
important that the clinical scientist can consult a pathologist at any
time in case of doubt concerning the location of the tumor cell
area.
ALK IHC, if carefully clinically validated according to ISO
15189, may be considered as a screening method to select
specimens for ALK FISH testing [15]. It is a cost-effective
screening tool which correlated significantly with ALK FISH,
using a number of antibodies including the 5A4 and D5F3 [25,31–
33]. However, discrepancies are reported also and need to be
elucidated [34]. The 5A4 and D5F3 antibodies were the most
frequently used clones in our study and revealed the smallest error
rates, which is in accordance with literature [32,33] and the
findings of a recent NordiQC assessment [35]. Not surprisingly
however, the error rates for IHC were greater than for FISH.
Recently different validation projects for ALK IHC tests were
done in collaboration with a lot of laboratories [36]. Moreover, on
the website of NORDIQC (http://www.nordiqc.org/), advice on
IHC staining protocols is given for several antibody clones.
Table 5. ALK IHC results.
Round Sample ID
ALK
rearrangement
status
Average
IHC score
Standard
deviation IHC
score Number of FP/FN
Round 1 LUNG 12.101 positive 154 53 2 (7%)
LUNG 12.102 positive 113 73 6 (22%)
LUNG 12.103 negative 15 51 2 (7%)
LUNG 12.104 negative 24 49 5 (17%)
LUNG 12.105 positive 118 61 3 (10%)
LUNG 12.106 negative 25 53 6 (21%)
LUNG 12.107 positive 154 62 2 (7%)
LUNG 12.108 negative 13 32 4 (14%)
Average / / / 3,8 (13,1%)
Round 2 LUNG12.201 negative 18 52 5 (12%)
LUNG12.202 negative 16 51 5 (11%)
LUNG12.203 negative 5 22 2 (5%)
LUNG12.204 negative 6 23 2 (4%)
LUNG12.205 negative 18 47 7 (16%)
LUNG12.206 negative 1 4 0 (0%)
LUNG12.207 negative 9 34 4 (9%)
LUNG12.208 positive 163 58 4 (9%)
LUNG12.209 positive 137 69 7 (16%)
LUNG12.210 negative 2 11 1 (2%)
LUNG12.211 positive 143 68 6 (13%)
LUNG12.212 negative 1 6 1 (2%)
Average / / / 3,7 (8,3%)
FP, false positives; FN, false negatives.
doi:10.1371/journal.pone.0112159.t005
Table 6. Scheme error rates per subscheme for both pilot rounds.
Subscheme Error rate round 1* Error rate round 2*
Digital ALK FISH 3,6% 0,5% due to FP 1,1% 0,8% due to FP
3,1% due to FN 0,3% due to FN
ALK FISH TMA 7,3% 0,5% due to FP 5,2% 4,0% due to FP
6,7% due to FN 1,2% due to FN
ALK IHC 13,0% 7,4% due to FP 8,2% 5,0% due to FP
5,6% due to FN 3,2% due to FN
*Error rate = (number of FP + number of FN)/total number of informative results FP, false positives; FN, false negatives.
doi:10.1371/journal.pone.0112159.t006
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Our study demonstrates improvement of ALK testing after only
two EQA rounds. This suggests that laboratories constructively use
the assessors’ feedback from the previous round to enhance their
performance. Participation in EQA facilitates rapid exposure of
errors and the timely implementation of corrective and preventive
actions. However, other factors such as increased expertise and
experience may play a part. It is expected that larger datasets,
spanning a larger number of EQA participations will demonstrate
a statistically significant improvement. On scheme level, the error
rates for both ALK FISH and ALK IHC were lower in the second
round and the ALK FISH digital scheme demonstrated an error
rate of only 1,1%. Error rates for ALK FISH TMA and ALK IHC
were still high (.5%), which stresses the need for continued
education through EQA. Progress was also seen on individual
laboratory level. For FISH analysis, improvements were observed
both in the number of errors made and in enumeration practices.
Reporting of test results should take into account sample
adequacy relative to the assay performance characteristics and
limitations, and clinical reports should be readily interpretable by
non-expert clinicians [19,21]. Previous EQA schemes have
exposed existing deficiencies in clinical reporting [18,37]. Our
results show that the content of reports for ALK rearrangement
detection should be improved. Especially, a case-specific clinical
interpretation, predicting the effect of the rearrangement status on
therapy response, should be integrated in each report since a clear
and concise assessment of the clinical implications of the result is
crucial to fully inform treatment options.
Maintenance of quality assurance measures, including stringent
internal quality controls and continued education by repeated
EQA participations is essential to ensure high testing quality and
rapid exposure of errors in order to warrant appropriate treatment
choices. This article has demonstrated improvement in the
performance of ALK FISH and ALK IHC in two consecutive
EQA rounds. Several recommendations were made to improve
the quality of ALK testing.
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